RxDoctor Payments Data

Vance Wright Browne, MD

Medical Oncology · Port Charlotte, FLNPI 1528059227

Payments from drug & device makers

$1,565,482in general payments, 2019–2025

Across 462 payments — averaging $3388.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$347K
  • Daiichi Sankyo Inc.$248K
  • AstraZeneca$235K
  • Pfizer$217K
  • Genmab U.S., Inc.$193K
  • Genentech, Inc.$164K
  • plus $161K from 39 others
$5,867in research payments, 2019–2025

Across 2 payments — averaging $2933.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K

What the payments were for

  • Food & beverage$3,23895%
  • Education$1785%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,565,482 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$4,359,575
Medicare patients
1,334
Services billed
275,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide38$717,296
BrukinsaZanubrutinib31$415,766
IbrancePalbociclib24$373,975
PomalystPomalidomide12$279,850
LynparzaOlaparib20$255,185
XtandiEnzalutamide14$188,102
VerzenioAbemaciclib11$151,962
VenclextaVenetoclax18$135,568
JaypircaPirtobrutinib13$134,386
TasignaNilotinib Hcl12$118,322
EliquisApixaban74$63,589
ProcritEpoetin Alfa19$48,191
Abiraterone Acetate20$36,291
XareltoRivaroxaban23$26,614
Letrozole260$6,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$268$717,29638 claims
PfizerIbrance, Eliquis$217,270$437,56398 claims
Beigene USA, Inc.Brukinsa$44$415,76631 claims
Lilly USA, LLCVerzenio, Jaypirca, Olanzapine$22$286,86057 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$547$279,85012 claims
AstraZenecaLynparza$234,806$255,18520 claims
Astellas Pharma US IncXtandi$32$188,10214 claims
AbbVieVenclexta$143$135,56818 claims
NovartisTasigna$81$118,32212 claims
Johnson & JohnsonProcrit, Xarelto$412$74,80542 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$54$36,29120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →